TCGA-22-5492-01A-01R-1635-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.470
- INTERFERON_ALPHA_RESPONSE+0.440
- MITOTIC_SPINDLE+0.430
- TGF_BETA_SIGNALING+0.430
- OXIDATIVE_PHOSPHORYLATION+0.420
- PI3K_AKT_MTOR_SIGNALING+0.400
- E2F_TARGETS+0.390
- INTERFERON_GAMMA_RESPONSE+0.390
- ALLOGRAFT_REJECTION+0.340
- IL6_JAK_STAT3_SIGNALING+0.330
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.350
- ANGIOGENESIS-0.270
- COAGULATION-0.250
- MYOGENESIS-0.200
- KRAS_SIGNALING_DN-0.140
- MYC_TARGETS_V2-0.130
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.090
- XENOBIOTIC_METABOLISM-0.010
- SPERMATOGENESIS+0.000
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C9523C23-CF9B-4C33-A256-4106AD46729D | — | — | 0.854 |
| 2 | 6292335B-7CBB-45BE-AA2A-B39FFDA8768D | — | — | 0.844 |
| 3 | 57AA1143-0FA1-4197-8CBE-517F6B885753 | — | — | 0.838 |
| 4 | TCGA-XF-AAMQ-01A-11R-A42T-07 | — | — | 0.838 |
| 5 | 0F8BE394-BA6A-401C-87D0-9B3CF50FB0C8 | — | — | 0.829 |
| 6 | AD62B8A4-6AB8-4C99-80F5-98A1C085027D | — | — | 0.826 |
| 7 | MNG1200 | — | — | 0.815 |
| 8 | SRR934830 | — | — | 0.813 |
| 9 | 5EC64886-2295-497A-BEE8-8AA17D8DADF1 | — | — | 0.811 |
| 10 | SRR934946 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.430 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.430 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.320 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.280 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.240 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.230 | Idelalisib | — uncovered |
| COMPLEMENT | 0.220 | Inavolisib | — uncovered |